Logo

Innovent Biologics Reports Acceptance of BLA for IBI-305 (bevacizumab- biosimilar) from NMPA (CFDA) to Treat NSCLC

Share this

Innovent Biologics Reports Acceptance of BLA for IBI-305 (bevacizumab- biosimilar) from NMPA (CFDA) to Treat NSCLC

Shots:

  • The BLA is based on two P-III study results assessing efficacy- safety and PK of IBI-305 vs bevacizumab in patients with advanced non-sq NSCLC and has demonstrated in meeting 1EPs with bio-similarity
  • Innovent has received three NMPA acceptance including IBI-305 namely Tyvyt (sintilimab injection) and IBI-303 (adalimumab- biosimilar) in H2’18 for ankylosing spondylitis (AS)- rheumatoid arthritis (RA) & psoriasis and r/r classical Hodgkin's lymphoma respectively
  • Avastin’s biosimilar IBI-305 (bevacizumab) is an anti-VEGF mAb- involved in inhibiting PI3K-Akt/PKB & Ras-Raf-MEK-ERK pathways and targeted for NSCLC- colorectal cancer and other malignant tumors

  Ref: PRNewswire | Image: Innovent

 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions